Back to X-Linked Lymphoproliferative Syndrome

X-Linked Lymphoproliferative Syndrome — Clinical Trials

MONDO:00106273 activeLast updated: Mar 15, 2026, 6:35 PM

Trial Landscape

X-Linked Lymphoproliferative Syndrome has an emerging clinical trial program, driven by drug treatment and biological therapy.

Recruiting

Active Trials

By Approach

Drug Treatment3

Biological Therapy3

By Phase

Phase 1

Phase 2

1 trials are observational or have no phase designation.

Sponsor Types

Academic/Other4

Trial Locations

United States4 trials

Trials often recruit across multiple countries, so totals exceed the trial count.

3 Trials

Phase 2Active, Not Recruiting

NCT01821781

Immune Disorder HSCT Protocol

Sponsor:Washington University School of Medicine

United StatesStarted: Apr 2013Est. completion: Apr 2026Updated: Feb 2026

Phase 1Active, Not Recruiting

NCT01494103

Administration of Donor T Cells With the Caspase-9 Suicide Gene

Sponsor:Baylor College of Medicine

United StatesStarted: Nov 2011Est. completion: May 2029Updated: Jul 2025

Not ApplicableActive, Not Recruiting

NCT01652092

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Sponsor:Masonic Cancer Center, University of Minnesota

United StatesStarted: Sep 2012Est. completion: Dec 2026Updated: Jan 2026

Stay informed about clinical trials for X-Linked Lymphoproliferative Syndrome.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 15, 2026 at 6:35 PM